Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Next Previous
X
Search
Trial Profile

A First-In-Human Phase I, Open Label, Safety and Tolerability Study of Escalating Multiple Doses of Intratumoral MQ710, a Multi-Transgene Expressing Modified Vaccinia Virus Ankara-Based Virotherapy, Alone and in Combination With the Systemic Checkpoint Inhibitor Pembrolizumab in Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MQ 710 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Basal cell cancer; Carcinoma; Extramammary Paget disease; Haemangiosarcoma; Head and neck cancer; Kaposi's sarcoma; Malignant melanoma; Merkel cell carcinoma; Solid tumours; Squamous cell cancer
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 25 Jul 2024 Planned number of patients changed from 56 to 5.
    • 25 Jul 2024 Status changed from planning to active, no longer recruiting.
    • 18 May 2023 Planned End Date changed from 4 May 2025 to 4 May 2028.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top